Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Have Glaukos Corp. insiders bought shares recently?
No open-market purchase by an insider of Glaukos Corp. was filed in the last 90 days. The latest on record was on Nov 22, 2017.
How often do Glaukos Corp. insiders buy and sell shares?
Since 2015, Glaukos Corp. insiders reported 6 open-market purchases and 398 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2017.
Who is selling Glaukos Corp. stock?
In the last 90 days, 5 insiders of Glaukos Corp. (GKOS) reported 46 open-market sales worth $69.2M in total on SEC Form 4. The largest seller by value was Thomas William Burns, with $42.6M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade GKOS?
No trade in Glaukos Corp. (GKOS) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+149.3% (+$142.11) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $95.20 on Nov 20, 2025 to $237.31 on Nov 20, 2026 (+149.3%). Disclosed in this range: 0 insider trades, 46 pre-arranged insider sales, 0 Congress trades, and 23 13F position changes for 4 quarters ending in it.
$50$100$150$200$300$237.31
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 46 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in San Clemente, California.
Last 12 months
+149.3%
S&P 500 +5.7% over the same dates
Market value
$14B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 4.48M shares sold short (7.6% of shares outstanding), +3.2% vs the previous count, 2.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
New federal contracts from the last 12 months add up to 0.04% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Since Nov 18, 2025, GKOS is up 159.0% and the index fund is up 4.5%: 154 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much GKOS moves
A usual day
±1.5%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.8%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−13.5%May 22, 2026
Largest one-day rise
+33.6%Oct 29, 2026
Deepest fall of the year
−28.4%From the close of May 15, 2026 to Jun 1, 2026.
Days of 5% or more
21Out of 252 sessions, in either direction.
Beta 1.0(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Insider buying and selling since 2015
Insiders of Glaukos Corp. reported 6 open-market purchases and 398 sales since 2015; purchases in 3 different years, most recently 2017.
Year
Bought
Sold
2026
—
$69.2M46×46 trades
2025
—
$3.66M10×10 trades
2024
—
$46.7M88×88 trades
2023
—
$35.4M47×47 trades
2022
—
$178K1×1 trade
2021
—
$9.39M14×14 trades
2020
—
$11.8M6×6 trades
2019
—
$9.47M22×22 trades
2018
—
$95.1M46×46 trades
2017
$50K1×1 trade
$119M63×63 trades
2016
$40K1×1 trade
$72.4M55×55 trades
2015
$187K4×4 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Glaukos Corp. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 19 open-market sales (about $23M, in 6 filings, by 3 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 14 open-market sales (about $5.95M, in 8 filings). (Glaukos Corp. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 14 new or larger positions and 10 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. 2 federal contract awards to the company were recorded in the 12 months, with about $190K obligated so far. A contract amount is what the agency obligated, not revenue. FINRA short interest for GKOS on the settlement date of Oct 30, 2026 was 4,483,891 shares (+3.24% on the previous report), about 2.85 days of average volume.
Company reports, price and press. Glaukos Corp. filed a Form 8-K on Oct 28, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors. Glaukos Corp. filed a Form 8-K on Jul 29, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Who holds it. 365 funds reported a stake in Glaukos Corp. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (15.8% of the value reported), Jupiter Topco LLC (8.0% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.5% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Glaukos Corp. filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 19 open-market sales (about $23M, in 6 filings, by 3 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 14 open-market sales (about $5.95M, in 8 filings).
The largest sale: Joseph E Gilliam, PRESIDENT & COO, about $4.55M, filed Nov 17, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 14 new or larger positions and 10 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
2 federal contract awards to the company were recorded in the 12 months, with about $190K obligated so far. A contract amount is what the agency obligated, not revenue.
FINRA short interest for GKOS on the settlement date of Oct 30, 2026 was 4,483,891 shares (+3.24% on the previous report), about 2.85 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 22,360 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $12M for its principal executive officer, and an average of $4.71M for the other named executive officers.
Company reports, price and press
Glaukos Corp. filed a Form 8-K on Oct 28, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Glaukos Corp. filed a Form 8-K on Jul 29, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Glaukos Corp. filed 0 open-market purchases and 39 open-market sales (about $68.7M, in 6 filings, by 5 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 7 open-market sales (about $500K, in 2 filings). (Glaukos Corp. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 30 days show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for GKOS on the settlement date of Oct 30, 2026 was 4,483,891 shares (+3.24% on the previous report), about 2.85 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 22,360 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Glaukos Corp. filed a Form 8-K on Oct 28, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors. Its announcing sentence reads: "Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026."
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Glaukos Corp. filed 0 open-market purchases and 39 open-market sales (about $68.7M, in 6 filings, by 5 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 7 open-market sales (about $500K, in 2 filings).
The largest sale: Thomas William Burns, CHAIRMAN & CEO, about $9.41M, filed Nov 21, 2026.
Funds and stakes
Fund 13F filings recorded in the 30 days show 1 new or larger position and 0 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for GKOS on the settlement date of Oct 30, 2026 was 4,483,891 shares (+3.24% on the previous report), about 2.85 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 22,360 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $12M for its principal executive officer, and an average of $4.71M for the other named executive officers.
Company reports, price and press
Glaukos Corp. filed a Form 8-K on Oct 28, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Its announcing sentence reads: "Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026."
Latest results: quarter ending Sep 30, 2026
Revenue
$211M
+58.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$36M
This quarter $36.5M, a year earlier −$11.7M
Net debt
—
Debt —, cash $162M, at Sep 30, 2026
Net income, last 12 months
−$170M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2026.
Glaukos Corp. filed a Form 8-K on Apr 29, 2026 (Items 2.02, 7.01) that OQRO classes as: reported its results, and shared information with investors.
Press coverage listed by Finnhub: "Why Glaukos Doubters Were Wrong Before A 165% Gain" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "What Drove Glaukos Stock's 48% Rally Since the End of September?" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "Could You Have Held Glaukos Stock Through Its Falls?" (Yahoo, Nov 14, 2026).
GKOS closed at $233.08 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $166.96 to $233.08, a change of +39.6%.
Who holds it
365 funds reported a stake in Glaukos Corp. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (15.8% of the value reported), Jupiter Topco LLC (8.0% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.5% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Press coverage: "Glaukos Corporation Outlines Product Roadmap and Commercial Updates in November 2026 Investor Presentation" (Fintel, Nov 6, 2026).
Press coverage: "SPDR S&P MidCap 400 ETF (MDY) Adds Glaukos and United Therapeutics on Wednesday" (Yahoo, Nov 6, 2026).
Press coverage: "What iShares Russell 2000 Index Fund (IWM) Bought: Glaukos Leads on Wednesday" (Yahoo, Nov 6, 2026).
Glaukos Corp.'s share price fell 10.8% on Nov 5, 2026 (close $219.98, from $246.70), about 5 times its usual one-session change.
Around that move, the same day, a headline in Yahoo read: "iShares Core S&P Mid-Cap (IJH) Adds Glaukos and TechnipFMC on Nov. 3".
Glaukos Corp.'s share price rose 33.6% on Oct 29, 2026 (close $242.48, from $181.43), about 19 times its usual one-session change.
Around that move, the day before, the company's press release read: "Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...".
GKOS closed at $237.31 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $176.85 to $237.31, a change of +34.2%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
A filing or headline published around a price move is not proof that it caused the move; OQRO lists it as published.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Oct 28, 2026. Quarterly reports are not audited. Read the filing
By product or service
Glaucoma$152M72%
+38% on the same quarter a year earlier ($110M)
Corneal Health$59M28%
+154% on the same quarter a year earlier ($23.3M)
Total revenue$211M+58%
By region
United States$175M83%
+72% on the same quarter a year earlier ($101M)
International$36.2M17%
+13% on the same quarter a year earlier ($32.1M)
Total revenue$211M+58%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 23, 2026. Read the filing
By product or service
Glaucoma$421M83%
+39% on the year before ($303M)
Corneal Health$86.4M17%
+7.7% on the year before ($80.2M)
Total revenue$507M+32%
By region
United States$375M74%
+39% on the year before ($270M)
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
From “Overview”, in the company's words
We are an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless platform therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device commercially in 2012. In 2024, we commenced commercialization activities for iDose TR, an intracameral procedural pharmaceutical implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time.
What the section covers (34 headings)
Overview
Financial Overview
Recent Developments
Market and Business Update
Impact of the Current Global Economic Environment
Developments Impacting Reimbursement Rates and Coverage
Business Outlook
Components of Results of Operations
Net Sales
Cost of Sales
Selling, General and Administrative
Research and Development
Acquired In-Process Research and Development
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026 and Form 10-Q filed Oct 28, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 42.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.2% on ATS, 12.0% with other brokers), close to its 26-week average of 43.7%. Weeks of Sep 21 to Oct 16, 2026.
International
$132M26%
+17% on the year before ($113M)
Total revenue$507M+32%
Non-Operating Income (Expense), Net
And 20 more headings in the filing.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (16.2%), INTELLIGENT CROSS LLC (11.4%), SIGMA X2 (8.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Risk factors in the annual report
Latest annual report filed Feb 23, 2026, compared with the one filed Feb 25, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
We have incorporated and continue to further incorporate artificial intelligence into our internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business.
No longer listed (1 heading from the year before)
If we incur future indebtedness, our obligation to service the indebtedness could limit the cash flow available for our operations and have other consequences that could adversely affect our business, and we may not have sufficient cash flow from our business to pay our debt obligations.
Legal proceedings (Item 3)
On September 17, 2025, the Company filed a complaint against SpyGlass Pharma, Inc. (SpyGlass) in the United States District Court for the Central District of California and its Vice President of Clinical Research, Long Doan (Case No. 8:25-cv-02105) (the Complaint). The Company asserts two claims for relief against SpyGlass: trade secret theft under the United States Defend Trade Secrets Act and unfair competition under California’s unfair competition statute. The Company asserts three claims against Mr.
Source: SEC EDGAR, Form 10-K filed Feb 23, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.